# DIVISLAB (DIVISLAB) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/divislab

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹9,375
- Change: +0.56%
- As of: 2026-09-18
- 1D return: +0.56%
- 5D return: -0.67%
- 1M return: +9.39%
- Latest complete quarter: fy27_q1

## Faxioms Analysis

_As of 2026-09-18_

### Technical Outlook

As of September 18, 2026, DIVISLAB's technical stance is primarily bullish across multiple timeframes, with the daily close at ₹9375.0. The daily, weekly, and monthly timeframes show alignment, with prices trading above key moving averages (EMA 20, EMA 50, SMA 20, SMA 50, SMA 200) and the Supertrend indicator, indicating a consistent uptrend. Daily momentum appears strong, with the ADX at 56.19 and positive DI (33.75) significantly above negative DI (17.95). The stock is positioned near the upper end of its recent trading range, with the position in the 252-day range at 0.94. The annualized volatility is 0.26, and the current drawdown is -0.02, suggesting moderate risk within the uptrend.

Nearest overhead resistance is observed at ₹9417.5, a 0.45% increase from the current price. Key support is identified at ₹9276.5, approximately 1.05% below the current price. Recent market activity shows a balance of events over the last 30 days, with one downside event, one neutral event, and one positive attention event. Active chart patterns include a monthly Harami and a weekly Doji, which may warrant monitoring for potential shifts in momentum.

Key conditions to watch include price action relative to the nearest resistance at ₹9417.5 and support at ₹9276.5. A sustained move above resistance could reinforce the bullish trend, while a break below support might signal a potential pullback. Monitoring the ADX and DI readings will be important to gauge the strength and direction of the trend.

- Daily close on September 18, 2026, was ₹9375.0.
- Prices are above daily, weekly, and monthly moving averages and Supertrend.
- Nearest resistance is at ₹9417.5 (0.45% above current price).
- Nearest support is at ₹9276.5 (1.05% below current price).
- Annualized volatility stands at 0.26.

- Harami
- Doji
- Bullish Engulfing Reversal
- Morning Star

### News Context

In the week ending September 18, 2026, Capitalmind Flexi Cap Fund reported adding Divi’s Laboratories to its portfolio during August. This fund's strategy involves adjusting its holdings across various sectors, with healthcare being a significant area of focus. Separately, a report on India's highest-paid CEOs for the fiscal year 2026 highlighted compensation packages, though Divi’s Laboratories' specific executive compensation was not detailed in the provided evidence.

- Capitalmind Flexi Cap Fund added Divi’s Laboratories to its portfolio in August.
- Healthcare represented the largest sector allocation in the Capitalmind Flexi Cap Fund's portfolio.
- A report identified India's highest-paid CEOs for FY26, but did not specify Divi’s Laboratories' executive compensation.

- Capitalmind Flexi Cap Fund adds Divi’s Laboratories, Bajaj Auto and 3 other stocks in August
- India’s highest-paid CEOs in FY26: Who took home the biggest pay packages

### What Changed

As of September 18, 2026, Divi's Laboratories (DIVISLAB) on the NSE has seen a slight increase in its stock price, moving from ₹9,323.0 to ₹9,375.0. Recent news indicates that the Capitalmind Flexi Cap Fund added Divi's Laboratories to its portfolio in August. Separately, a report on India's highest-paid CEOs for FY26 mentioned compensation packages, though Divi's Laboratories was not explicitly featured in the provided excerpt regarding specific CEO earnings.

- Divi's Laboratories' stock price increased to ₹9,375.0 on September 18, 2026, from ₹9,323.0 previously.
- Capitalmind Flexi Cap Fund added Divi's Laboratories to its portfolio in August.
- Divi's Laboratories is listed on the NSE.

- Capitalmind Flexi Cap Fund adds Divi’s Laboratories, Bajaj Auto and 3 other stocks in August
- India’s highest-paid CEOs in FY26: Who took home the biggest pay packages

### Official Filings

Divi's Laboratories Limited disclosed its financial results for the quarter ended June 30, 2026 (Q1 FY27) on August 1, 2026. The company reported consolidated total income of ₹3,144 crores and a profit after tax of ₹902 crores. During the same period, the Board of Directors approved the appointment of Mr. B. Vara Prasad and Mr. J. Srinivasa Rao as Senior Management Personnel, effective August 1, 2026. The company also held an earnings conference call on August 1, 2026, to discuss these results, with the transcript and audio recording made available on its website. Separately, on August 26, 2026, an immediate relative of a promoter sold 200 equity shares at ₹1,770,000 per share on the NSE. Additionally, on September 12, 2026, the company published newspaper advertisements regarding a special window for the transfer and dematerialisation of physical shares, as per SEBI guidelines.

- On August 1, 2026, Divi's Laboratories reported Q1 FY27 consolidated total income of ₹3,144 crores and profit after tax of ₹902 crores.
- The Board approved the appointment of Mr. B. Vara Prasad and Mr. J. Srinivasa Rao as Senior Management Personnel, effective August 1, 2026.
- On August 26, 2026, an immediate relative of a promoter sold 200 equity shares for ₹1,770,000.
- On September 12, 2026, the company announced a special window for physical share transfer and dematerialisation.

- Divi's Laboratories Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication
- DIVISLAB|Divi's Laboratories Limited|Original|Regulation 7 (2)|IT_2132_WebXMLFile_20260831_110842619.xml|IT_2132_20260831_110842670_WEB.html|5150|22290|-
- DIVISLAB|Divi's Laboratories Limited|Original|Regulation 7 (2)|IT_2132_WebXMLFile_20260828_112328721.xml|IT_2132_20260828_112328755_WEB.html|5150|22290|-
- DIVISLAB|Divi's Laboratories Limited|Original|Regulation 7 (2)|IT_2132_WebXMLFile_20260821_111254441.xml|IT_2132_20260821_111254480_WEB.html|5142|22282|-
- Divi's Laboratories Limited has informed the Exchange about Transcripts - earnings or quarterly calls |SUBJECT: Analyst/Investor Meet Para A-XBRL

### Fundamentals

Divi's Laboratories reported its financial results for the periods ending Q3 FY2025-26, Q4 FY2025-26, and Q1 FY2026-27. Revenue from operations showed significant fluctuation, with ₹2,604 crore in Q3 FY2025-26, a substantial increase to ₹10,560 crore in Q4 FY2025-26, followed by a decrease to ₹3,080 crore in Q1 FY2026-27. Profit Before Tax followed a similar pattern, reported at ₹780 crore for Q3 FY2025-26, ₹3,388 crore for Q4 FY2025-26, and ₹1,180 crore for Q1 FY2026-27. The company's net profit, or Profit Loss For Period, was ₹583 crore in Q3 FY2025-26, ₹2,568 crore in Q4 FY2025-26, and ₹902 crore in Q1 FY2026-27. Finance costs remained relatively low across these periods, at ₹6 crore, ₹23 crore, and ₹6 crore, respectively. Other expenses also varied, recorded at ₹402 crore, ₹1,584 crore, and ₹431 crore for the respective quarters. The tax expense followed the trend of profitability, amounting to ₹197 crore, ₹820 crore, and ₹278 crore.

- Revenue from operations was ₹2,604 crore in Q3 FY2025-26, ₹10,560 crore in Q4 FY2025-26, and ₹3,080 crore in Q1 FY2026-27.
- Profit Before Tax stood at ₹780 crore for Q3 FY2025-26, ₹3,388 crore for Q4 FY2025-26, and ₹1,180 crore for Q1 FY2026-27.
- Profit Loss For Period was reported as ₹583 crore in Q3 FY2025-26, ₹2,568 crore in Q4 FY2025-26, and ₹902 crore in Q1 FY2026-27.
- Finance Costs were ₹6 crore in Q3 FY2025-26, ₹23 crore in Q4 FY2025-26, and ₹6 crore in Q1 FY2026-27.
- Other Expenses were ₹402 crore in Q3 FY2025-26, ₹1,584 crore in Q4 FY2025-26, and ₹431 crore in Q1 FY2026-27.

### Bull Case

Divi's Laboratories' technical indicators suggest a positive trend across multiple timeframes. The daily trend shows the closing price of ₹9375.0 is above its 20-day Exponential Moving Average (EMA) of ₹9120.83 and its 50-day Simple Moving Average (SMA) of ₹8401.76, with upward slopes indicating momentum. The Supertrend indicator is also 'bullish' on a daily basis. This positive momentum extends to the weekly and monthly charts, where the Supertrend direction is also 'bullish', with the closing price trading above key moving averages. The stock has demonstrated significant returns over the past year, with a 1-year return of 53% and a Year-to-Date (YTD) return of 48%. Additionally, the fund Capitalmind Flexi Cap Fund added Divi's Laboratories to its portfolio in August, indicating institutional interest.

- The daily Supertrend indicator is 'bullish' as of 2026-09-18.
- The closing price of ₹9375.0 on 2026-09-18 is above the 20-day EMA (₹9120.83) and 50-day SMA (₹8401.76).
- The stock has delivered a 1-year return of 53% and a YTD return of 48%.
- Capitalmind Flexi Cap Fund added Divi's Laboratories to its portfolio in August.

- Capitalmind Flexi Cap Fund adds Divi’s Laboratories, Bajaj Auto and 3 other stocks in August
- India’s highest-paid CEOs in FY26: Who took home the biggest pay packages

### Bear Case

The company's stock is exhibiting elevated volatility, as indicated by an annualized volatility of 26% and a current drawdown of -2%. The maximum drawdown observed has been -19%, suggesting potential for significant price fluctuations. While technical indicators show a bullish trend on daily, weekly, and monthly timeframes, the Average Directional Index (ADX) at 56.19 on the daily chart suggests strong trending momentum, which can also imply increased susceptibility to sharp reversals if the trend falters. The stock is trading near its nearest resistance level of ₹9417.5, which is 0.45% above the current price, indicating a potential ceiling in the short term.

- Annualized volatility stands at 26% as of 2026-09-18.
- The stock has experienced a maximum drawdown of -19%.
- The current drawdown is -2% as of 2026-09-18.
- The nearest resistance level is ₹9417.5, 0.45% above the current price.
- The daily ADX (14) is 56.19, indicating strong trending conditions.

- Capitalmind Flexi Cap Fund adds Divi’s Laboratories, Bajaj Auto and 3 other stocks in August
- India’s highest-paid CEOs in FY26: Who took home the biggest pay packages

### FAQs

**What were Divi's Laboratories' key financial results for the quarter ended June 30, 2026?**

For the quarter ended June 30, 2026, Divi's Laboratories reported consolidated total income of ₹3,144 crores and profit after tax of ₹902 crores. These results were discussed during an earnings conference call held on August 1, 2026.

**What recent insider trading activity has occurred at Divi's Laboratories?**

On August 26, 2026, K. Sridevi, an immediate relative of a promoter, sold 200 equity shares on the NSE for ₹1,770,000. Following this sale, she held 3,100 shares.

**How has Divi's Laboratories performed over different time horizons based on recent return data?**

As of September 18, 2026, Divi's Laboratories has shown varied returns across different periods. The company's year-to-date (YTD) return was 0.48, and its return over the last 6 months was 0.53. Over a longer period, the return over the last year was 0.53. Shorter-term returns include 0.09 for the last 3 months and 0.01 for the last month.

**What are the key technical indicators suggesting about Divi's Laboratories' current trend?**

Technical indicators suggest a bullish trend for Divi's Laboratories. On a daily timeframe, the Supertrend indicator is bullish, and the Exponential Moving Average (EMA) 20 slope is positive (103.59). Similarly, on a weekly timeframe, the Supertrend direction is bullish, with a positive EMA 20 slope of 811.9. The monthly trend also shows a bullish Supertrend direction.

- Capitalmind Flexi Cap Fund adds Divi’s Laboratories, Bajaj Auto and 3 other stocks in August
- India’s highest-paid CEOs in FY26: Who took home the biggest pay packages
- Divi's Laboratories Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication
- DIVISLAB|Divi's Laboratories Limited|Original|Regulation 7 (2)|IT_2132_WebXMLFile_20260831_110842619.xml|IT_2132_20260831_110842670_WEB.html|5150|22290|-
- DIVISLAB|Divi's Laboratories Limited|Original|Regulation 7 (2)|IT_2132_WebXMLFile_20260828_112328721.xml|IT_2132_20260828_112328755_WEB.html|5150|22290|-
- DIVISLAB|Divi's Laboratories Limited|Original|Regulation 7 (2)|IT_2132_WebXMLFile_20260821_111254441.xml|IT_2132_20260821_111254480_WEB.html|5142|22282|-
## Technical analytics

- As of: 2026-09-18
- Daily trend: Strong Uptrend
- Weekly trend: Moderate Uptrend
- Pivot point: ₹9,276.5
- Risk regime: Price Risk Currently Contained

### Support levels
- 8457.5
- 8233.5
- 6636

### Resistance levels
- 9467
- 9615
- 9417.5

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +0.56% |
| return_10 | +1.35% |
| return_1m | +9.16% |
| return_1y | +53.39% |
| return_20 | +9.39% |
| return_3m | +38.54% |
| return_5 | -0.67% |
| return_6m | +52.69% |
| return_since_start | +54.37% |
| return_ytd | +47.78% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | contained_risk |
| label | Price risk currently contained |
| summary | Recent drawdown and price variability remain within the producer's contained-risk thresholds. |
| maximum_drawdown | -18.53% |
| annualized_volatility | +25.95% |

## Quarterly financials

- Latest complete quarter: fy27_q1

# Revenue Up 27.8% and Profit Before Tax Up 60.9% Year-on-Year, After an Exceptionally Large Prior Quarter

Divi’s Laboratories Limited reported revenue from operations of ₹3,080 crore for the quarter ended 30 June 2026, a 27.8% increase from ₹2,410 crore in the same quarter a year ago. Profit before tax rose 60.9% to ₹1,180 crore, and profit after tax increased 65.5% to ₹902 crore. The quarter follows an unusually large preceding quarter (Q4 FY2026), which delivered revenue of ₹10,560 crore.

## Revenue and Profit

Revenue from operations grew ₹670 crore compared with Q1 FY2026. Profit before tax (PBT) increased from ₹733 crore to ₹1,180 crore over the same period, while profit after tax (PAT) rose from ₹545 crore to ₹902 crore.

On a sequential basis, revenue fell 70.8% from the Q4 FY2026 level of ₹10,560 crore. That preceding quarter’s revenue was substantially higher than any other quarter in the available series. The Q1 FY2027 revenue returned to a scale comparable with the year-earlier quarter, and the year-on-year comparison provides the clearest view of the business’s growth.

## Expenses and Profitability

For Q1 FY2027, the company reported the following major expense items:

- Cost of materials consumed: ₹1,503 crore
- Employee benefit expense: ₹408 crore
- Other expenses: ₹431 crore
- Depreciation, depletion and amortisation: ₹133 crore
- Finance costs: ₹6 crore

Other expenses rose 11.9% from ₹385 crore in Q1 FY2026, a slower increase than the 27.8% revenue growth. Finance costs were ₹6 crore, compared with ₹3 crore in the prior-year quarter and ₹23 crore in the immediately preceding Q4 FY2026.

The PBT margin (PBT as a percentage of revenue from operations) widened to 38.3% from 30.4% a year earlier. The PAT margin moved to 29.3% from 22.6%. The effective tax rate was 23.6% (₹278 crore tax on PBT of ₹1,180 crore), down from 25.6% (₹188 crore on ₹733 crore) in Q1 FY2026.

## Earnings per Share

Basic and diluted earnings per share were each ₹33.95, compared with ₹20.49 in Q1 FY2026, a 65.7% increase. The basic and diluted figures being identical suggests there are no outstanding instruments with a dilutive effect.

## Management Commentary

Divi's Laboratories reported strong Q1 FY27 results, with consolidated total income rising 24% YoY to ₹3,144 Cr and PAT surging 65% to ₹902 Cr, driven by robust revenue growth in its core API and intermediates business. On a standalone basis, revenue from operations grew to ₹2,974 Cr from ₹2,357 Cr YoY, while PAT increased to ₹891 Cr from ₹557 Cr. Management highlighted a forex loss of ₹7 Cr for the quarter, compared to a gain of ₹39 Cr in the prior year, which impacted profitability. The company also strengthened its leadership by appointing two senior management personnel in procurement roles, effective August 1, 2026, signaling a focus on supply chain and operational efficiency.

## Key Takeaway

Revenue and profit for the quarter ended 30 June 2026 were materially higher than in the year-ago period, with profit growing faster than revenue and pushing margins higher. The steep sequential decline from the prior quarter reflects the outsized scale of that period and not an indication of weakening performance. Other expenses increased at a rate well below revenue growth, and the effective tax rate was slightly lower year-on-year.

### Ratios

## Official filings

- 2026-09-12 — Generic Announcement: Divi's Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/DIVISLAB_12092026115855_Special_Window_PaperAdv.pdf)
- 2026-08-31 — Official Filing: Divi's Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/IT_2132_WebXMLFile_20260831_110842619.xml)
- 2026-08-28 — Official Filing: Divi's Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/IT_2132_WebXMLFile_20260828_112328721.xml)
- 2026-08-21 — Official Filing: Divi's Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/IT_2132_WebXMLFile_20260821_111254441.xml)
- 2026-08-06 — Generic Announcement: Divi's Laboratories Limited held an earnings conference call on August 1, 2026, to discuss results for the quarter ended June 30, 2026. The company reported consolidated total income of ₹3,144 crores and profit after tax of ₹902 crores for Q1 FY27. Management discussed progress on custom synthesis projects, peptide business expansion, and the role of Unit 3 in their manufacturing network. Challenges related to solvent costs and global logistics were also addressed. — [Official attachment](https://nsearchives.nseindia.com/corporate/DIVISLAB_06082026142802_Transcript_Concall_01082026.pdf)
- 2026-08-06 — Generic Announcement: Divi's Laboratories Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_2132_WebXMLFile_20260806_145641577.xml)
- 2026-08-03 — Generic Announcement: Divi's Laboratories Limited published its unaudited financial results for the quarter ended June 30, 2026, on August 2, 2026, in the Financial Express and Andhra Prabha newspapers. — [Official attachment](https://nsearchives.nseindia.com/corporate/DIVISLAB_03082026121144_Intimation_of_Newspaper_Publication_Q1FY27.pdf)
- 2026-08-01 — Generic Announcement: Divi's Laboratories Limited's Board of Directors approved unaudited financial results for the quarter ended June 30, 2026, reporting consolidated total income of ₹3,144 crores and profit after tax of ₹902 crores. The board also approved the appointment of Mr. B. Vara Prasad and Mr. J. Srinivasa Rao as Senior Management Personnel, effective August 01, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/DIVISLAB_01082026114235_Outcome_BoardMeeting_01082026_DivisLabs.pdf)
- 2026-08-01 — Generic Announcement: Divi's Laboratories Limited uploaded the audio recording of its Q1 FY27 earnings conference call, held on August 01, 2026, to its website. This disclosure is in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. — [Official attachment](https://nsearchives.nseindia.com/corporate/DIVISLAB_01082026154417_Intimation_Q1FY27EarningsCall_AudioRecording.pdf)
- 2026-08-01 — Generic Announcement: Divi's Laboratories Limited's Board of Directors approved unaudited financial results for the quarter ended June 30, 2026, reporting consolidated total income of ₹3,144 crores and profit after tax of ₹902 crores. The board also approved the appointment of Mr. B. Vara Prasad and Mr. J. Srinivasa Rao as Senior Management Personnel, effective August 01, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/DIVISLAB_01082026113144_Outcome_BoardMeeting_01082026_DivisLabs.pdf)
- 2026-08-01 — Official Filing: Divi's Laboratories Limited announced the appointment of two senior management personnel on August 1, 2026, following a board meeting. Mr. B. Vara Prasad was appointed General Manager (Engineering Purchase), and Mr. J. Srinivasa Rao was appointed General Manager (Raw Materials Purchase). Both individuals have extensive experience in the pharmaceutical procurement sector.
- 2026-07-31 — Generic Announcement: Divi's Laboratories Limited announced the cessation of two Senior Management Personnel, Mr. L. Ramesh Babu (Vice President, Procurement) and Mr. D. Madhu Babu (Vice President, Projects), due to retirement. Their cessation will be effective from the close of business hours on July 31, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/DIVISLAB_31072026091128_Regulation30Intimation31072026.pdf)
- 2026-07-31 — Official Filing: Divi's Laboratories Limited reported the retirement of two senior management personnel, Mr. Lingamneni Ramesh Babu, Vice President (Procurement), and Mr. Dandamudi Madhu Babu, Vice President (Projects), effective July 31, 2026. This change in management was disclosed on July 31, 2026.
- 2026-07-24 — Official Filing: Divi's Laboratories Limited will hold its Q1 FY2027 Earnings Conference Call on August 1, 2026, at 14:00:00. The virtual event will discuss the company's Q1 FY2027 results. Contact Mr. M. Satish Choudhury at 914066966352 or cs@divislabs.com for more information.
- 2026-07-24 — Generic Announcement: Divi's Laboratories Limited will release its unaudited financial results for the quarter ended June 30, 2026 (Q1 FY27) on August 01, 2026. Following the results release, the company's management will host an earnings conference call on the same day, August 01, 2026, at 14:00 hrs IST to discuss financial performance. A transcript will be available on the company's website. — [Official attachment](https://nsearchives.nseindia.com/corporate/DIVISLAB_24072026103115_Q1FY27Concall_intimation_01082026.pdf)
- 2026-07-20 — Official Filing: Divi's Laboratories Limited will hold a board meeting on August 1, 2026, to consider unaudited standalone and consolidated financial results for the quarter ended June 2026. The trading window for securities will be closed from July 1, 2026, to August 3, 2026.
- 2026-07-17 — Generic Announcement: Divi's Laboratories Limited published a notice on July 17, 2026, in the Financial Express and Andhra Prabha regarding its 36th Annual General Meeting, e-voting, and the electronic dispatch of its Annual Report for 2025-26. — [Official attachment](https://nsearchives.nseindia.com/corporate/DIVISLAB_17072026124237_IntimationOfNewspaperPublication17072026.pdf)
- 2026-07-15 — Generic Announcement: Divi's Laboratories Limited will hold its 36th Annual General Meeting on August 10, 2026, via video conference. The agenda includes adopting financial statements for the year ended March 31, 2026, and declaring a dividend of ₹30 per equity share. The meeting will also address the re-appointment of directors Mr. N.V. Ramana and Dr. Kiran S. Divi. Remote e-voting will be open from August 6 to August 9, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/DIVISLAB_15072026173212_36thAGMNotice_DivisLabs.pdf)
- 2026-07-13 — Generic Announcement: Divi's Laboratories Limited announced its 36th Annual General Meeting will be held on August 10, 2026, via Video Conferencing/Other Audio-Visual Means. A record date for dividend and other information was also established. This notice was published on July 13, 2026, in the Financial Express and Andhra Prabha newspapers. — [Official attachment](https://nsearchives.nseindia.com/corporate/DIVISLAB_13072026115914_Newspaper_Publication_13072026.pdf)
- 2026-07-07 — Generic Announcement: Divi's Laboratories Limited submitted a certificate for the quarter ended June 30, 2026, confirming that securities received from depository participants for dematerialization were processed. KFin Technologies Limited, the Registrar & Share Transfer Agent, confirmed that securities were accepted, listed on BSE and NSE, and certificates were mutilated and cancelled within 15 days, with depositories substituted as registered owners. — [Official attachment](https://nsearchives.nseindia.com/corporate/DIVISLAB_07072026162826_Reg_74_DIVIS.pdf)
- 2026-07-06 — Shareholding Disclosure: Dr. Murali K. Divi, Promoter and Managing Director of Divi's Laboratories Limited, along with persons acting in concert, declared no encumbrance on shares directly or indirectly during the financial year ended March 31, 2026. The declaration lists Dr. Murali Krishna Prasad Divi, Swarnalatha Divi, Dr. Kiran Satchandra Divi, Nilima Prasad Divi, and Divi's Biotech Private Limited as persons acting in concert. — [Official attachment](https://nsearchives.nseindia.com/corporate/team_bbodade_28042026161059_DIVISLAB.pdf)
- 2026-06-30 — Generic Announcement: Divi's Laboratories Limited will close its trading window from July 01, 2026, until 48 hours after the declaration of its unaudited financial results for the quarter ended June 30, 2026. This closure is in accordance with the company's Code of Conduct for trading by designated persons and insiders. — [Official attachment](https://nsearchives.nseindia.com/corporate/DIVISLAB_30062026105211_Intimation_TradingWindowClosure_Q1FY27.pdf)
- 2026-06-11 — Generic Announcement: Divi's Laboratories Limited informed shareholders on June 11, 2026, about the deduction of Income Tax at source on dividends for the financial year 2025-26. The company sent communications on June 10, 2026, detailing the process and documentation for claiming exemptions. The recommended dividend is ₹30 per share, subject to shareholder approval at the AGM on August 10, 2026, with distribution planned after August 14, 2026. Shareholders must submit required tax documents by July 24, 2026, to ensure correct tax withholding rates are applied. — [Official attachment](https://nsearchives.nseindia.com/corporate/DIVISLAB_11062026091018_Intimation_about_TDS_deduction_on_dividend.pdf)
- 2026-06-04 — Generic Announcement: Divi's Laboratories Limited published newspaper advertisements on June 04, 2026, in the Financial Express and Andhra Prabha regarding the transfer of unclaimed dividends and equity shares to the Investor Education and Protection Fund (IEPF). This action is in compliance with Section 124(6) of the Companies Act, 2013. — [Official attachment](https://nsearchives.nseindia.com/corporate/DIVISLAB_04062026150550_NewspaperClippings_IEPFTransfer_04062026.pdf)
- 2026-05-29 — Generic Announcement: Divi's Laboratories Limited held an earnings conference call on May 23, 2026, to discuss financial results for the quarter and year ended March 31, 2026. The company reported a consolidated total income of ₹2,986 crores for the quarter and ₹11,067 crores for the full year. Profit after tax for the year was ₹2,568 crores. Management discussed challenges in raw material sourcing due to geopolitical tensions and increased freight costs, but noted their supply chain resilience. They also highlighted ongoing investments in capacity and technology, with capital work in progress at ₹2,113 crores as of March 31, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/DIVISLAB_29052026103543_Q4FY26_Transcript_of_EarningsCall23052026.pdf)

## News and market events

- 2026-09-18 — Economic Times: **Capitalmind Flexi Cap Fund adds Divi’s Laboratories, Bajaj Auto and 3 other stocks in August** — Capitalmind Flexi Cap Fund made five fresh additions and completely exited five stocks from its portfolio in August, while keeping its exposure unchanged in 27 stocks. The fund had 32 stocks across 17 sectors, with healthcare accounting for the largest allocation. Heres a look at the stocks added and exited, sector allocation and the funds performance since inception. — [Source](https://economictimes.indiatimes.com/mf/analysis/capitalmind-flexi-cap-fund-adds-divis-laboratories-bajaj-auto-and-3-other-stocks-in-august/articleshow/134328679.cms)
- 2026-09-17 — CNBC-TV18: **India’s highest-paid CEOs in FY26: Who took home the biggest pay packages** — Meet India’s highest-paid CEOs in FY26. From Persistent Systems' Sandeep Kalra crossing ₹388 crore to Angel One's Ambarish Kenghe posting a 10,000% spike, here are the 10 highest-paid business leaders in FY26 and their compensation packages. — [Source](https://www.cnbctv18.com/photos/business/indias-highest-paid-ceos-in-fy26-who-took-home-the-biggest-pay-packages-19993029.htm)
- 2026-09-08 — MONEYCONTROL: **Trade Spotlight: How should you trade Titagarh Rail Systems, AIA Engineering, Apollo Hospitals, Divis Labs, Blue Star, and others on September 8?** — Trade Spotlight — [Source](https://www.moneycontrol.com/news/business/markets/trade-spotlight-how-should-you-trade-titagarh-rail-systems-aia-engineering-apollo-hospitals-divis-labs-blue-star-and-others-on-september-8-14024785.html)
- 2026-09-01 — CNBC-TV18: **Symbiotec Pharmalab shares to list today; GMP signals 19% premium over IPO price** — If grey market trends are anything to go by, the stock could make a strong debut with a premium of around 19% over its issue price. The grey market premium (GMP) currently stands at ₹185, indicating an estimated listing price of around ₹1,173 per share, compared with the IPO price of ₹988. — [Source](https://www.cnbctv18.com/market/symbiotec-pharmalab-share-price-ipo-listing-today-premium-discount-gmp-signals-issue-price-nse-bse-19980955.htm)
- 2026-08-24 — The Hindu: **Symbiotec Pharmalab IPO sees subscription at 0.70x by mid-afternoon** — The employee reservation portion led with 1.19 times subscription; Retail Individual Investors subscription at 0.82 times, NII category is at 0.86 times. QIB remained the weakest segment at 0.35 times — [Source](https://www.thehindubusinessline.com/markets/symbiotec-pharmalab-ipo-sees-subscription-at-070x-by-mid-afternoon/article71384017.ece)
- 2026-08-24 — Economic Times: **Can Symbiotec Pharmalab IPO deliver long-term growth for high-risk investors?** — Symbiotec Pharmalab plans a ₹150 crore IPO to repay debt and expand operations. The company holds a global leadership position in corticosteroid and steroidal-hormone APIs. Its revenue primarily comes from international markets, with Europe being a significant contributor. Financials show steady revenue and EBITDA growth over recent years. Investors with a high-risk appetite may consider this long-term opportunity. — [Source](https://economictimes.indiatimes.com/markets/ipos/fpos/can-symbiotec-pharmalab-ipo-deliver-long-term-growth-for-high-risk-investors/articleshow/133448856.cms)
- 2026-08-15 — The Hindu: **India Inc throws up a pleasant surprise in Q1 as compared to gloom at the start of the quarter** — India Inc's Q1 performance shows strong revenue growth, defying initial gloom, despite challenges from rising input costs. — [Source](https://www.thehindubusinessline.com/portfolio/india-inc-throws-up-a-pleasant-surprise-in-q1-as-compared-to-gloom-at-the-start-of-the-quarter/article71350303.ece)
- 2026-08-10 — CNBC-TV18: **Why Hyundai, Ashok Leyland and ICICI Bank are among Macquarie's top picks** — Sandeep Bhatia of Macquarie Capital breaks down this quarter's earnings surprise across large and small caps, his top picks in autos and private banking, and a possible rotation between technology and power stocks tied to global AI valuations over the next 18 months. — [Source](https://www.cnbctv18.com/market/why-macquarie-sandeep-bhatia-hyundai-ashok-leyland-icici-bank-india-next-winners-divis-labs-nestle-shriram-transport-rbi-artificial-intelligence-itc-19965333.htm)
- 2026-08-03 — The Hindu: **Sensex today | Stock Market Live: Sensex rises 600 pts, Nifty near 24,600; ITC, IndiGo lead gainers; Muthoot Finance down 10%; PMI Manufacturing slips to near 5-year low in July** — Sensex, Nifty, Stock Price Live Updates: The fresh week began on a positive note for Indian stocks, thanks to softer crude oil prices and stable global markets. — [Source](https://www.thehindubusinessline.com/markets/sensex-nifty50-today-stock-market-live-updates-3rd-august-2026/article71298312.ece)
- 2026-08-03 — CNBC-TV18: **Q1 Results LIVE Updates: Maruti, Persistent, IOC react to earnings; SBI Funds, UPL, DLF report today** — Q1 Results LIVE Updates: SBI Funds Management, Ather Energy, Inox India, IREDA, DOMS Industries, DLF, Escorts Kubota, CAMS, NOCIL, Nazara Tech, PNC Infra, Torrent Power, UPL, Restaurant Brands Asia, PNC Infra, KIMS, KEI Industries, Jindal Stainless, Ethos, GSK Pharma, Bluejet Healthcare, Kansai Nerolac, JM Financial, Kalpataru, Dhanuka Agritech, Texmaco Rail, are among the companies reporting their earnings today. Results reactions will come from stocks like ITC, Maruti Suzuki, Muthoot Finance, Dixon tech, and many others. Watch this space for all the LIVE Q1 results updates. — [Source](https://www.cnbctv18.com/market/q1-results-live-updates-maruti-sbi-mf-upl-dlf-ireda-ioc-dixon-persistent-muthoot-cams-escorts-ather-abb-divis-share-price-liveblog-19959998.htm)
- 2026-08-03 — CNBC-TV18: **Sensex Today | Stock Market Live Updates: Nifty bulls set sights on 24,500 amidst crude cool-off, FCNR inflows** — Sensex Today | Stock Market Live Updates: The bulls, having ended the week with gains will now be eyeing two levels on the upside, 24,467, which is the recent swing high, and 24,500, which has been a psychological barrier, before the positional swing high of 24,601 could be retested. The Nifty Bank though, continues to struggle with 57,500 continuing to act as a hurdle. — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-today-oil-fcnr-rupee-itc-maruti-autos-ioc-divis-zee-stl-banks-share-price-liveblog-19959976.htm)
- 2026-07-31 — CNBC-TV18: **Sensex Today | Stock Market Live Updates: Nifty extends gains to 100 pts; PSU banks off lows** — Sensex Today | Stock Market Live Updates: We are the last half the week's trade, and the Indian markets are trading on a cautious note. The Nifty is looking to close the week in green, and is trading around 24,300. The Nifty Bank is trying to hold it together, now up around 100 points, moving around 57,250. TCS, Infosys and Wipro are the top laggards. — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-today-it-infosys-banks-tata-steel-swiggy-sun-pharma-mdl-bajaj-fin-share-price-liveblog-19958369.htm)

## Business profile

**Strategic vision:** Manufactures active pharmaceutical ingredients, intermediates, and nutraceuticals.

### Business segments
- **Generic APIs:** Divi's is a leading manufacturer of Generic APIs globally, offering over 30 commercial products and focusing on large-scale production.
- **Custom Synthesis:** Provides custom synthesis contract manufacturing services for APIs and intermediates to large pharmaceutical companies, handling high-potency compounds and high-energy reactions.
- **Nutraceuticals:** Supplies a comprehensive range of carotenoids and market-targeted vitamins for the nutritional, pharmaceutical, food/beverage, and feed industries.

### Competitive strengths
- Expertise in handling high-potency compounds and executing high-energy reactions.
- Large-scale production capabilities for APIs.
- Established global supply chain with long-term partnerships.
- Adherence to stringent global regulatory standards.

## Related stocks

- [360ONE (Financial Services)](https://faxioms.com/stocks/360one) — +1.11%
- [3MINDIA (Diversified)](https://faxioms.com/stocks/3mindia) — +4.81%
- [AADHARHFC](https://faxioms.com/stocks/aadharhfc) — -1.64%
- [AARTIIND](https://faxioms.com/stocks/aartiind) — +1.78%
- [AAVAS](https://faxioms.com/stocks/aavas) — -0.56%

## Freshness and sources

- Data as of: 2026-09-18
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/divislab
Markdown representation: https://faxioms.com/stocks/divislab?render=md